Close

Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma

Go back to Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announces FDA Approval for Abecma for Relapsed or Refractory Multiple Myeloma

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Mye

March 26, 2021 10:59 PM EDT

Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma1

In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1

Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1

PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS... More